(Q39325378)

11 September 2017

1 reference

title

Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy (English)

1 reference

11 September 2017

Silvia von Karstedt

1

1 reference

11 September 2017

Antonella Montinaro

series ordinal

2

1 reference

11 September 2017

Henning Walczak

series ordinal

3

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 May 2017

1 reference

11 September 2017

published in

Nature Reviews Cancer

1 reference

11 September 2017

volume

17

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

352-366

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc.2017.28

11 September 2017

exact match

0 references

cites work

Death receptor-ligand systems in cancer, cell death, and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

An endotoxin-induced serum factor that causes necrosis of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cachetin/TNF-alpha in septic shock and septic adult respiratory distress syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Lethal effect of the anti-Fas antibody in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Essential roles of the Fas ligand in the development of hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Identification and characterization of a new member of the TNF family that induces apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Safety and antitumor activity of recombinant soluble Apo2 ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Signalling pathways of the TNF superfamily: a double-edged sword

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Membrane-bound Fas ligand only is essential for Fas-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The TNF and TNF receptor superfamilies: integrating mammalian biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The receptor for the cytotoxic ligand TRAIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Characterization of two receptors for TRAIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

A novel receptor for Apo2L/TRAIL contains a truncated death domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

c-FLIPR, a new regulator of death receptor-induced apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Caspase-9, Bcl-XL, and Apaf-1 form a ternary complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Activation of NF-kappaB by FADD, Casper, and caspase-8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL regulates normal erythroid maturation through an ERK-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Compartmentalization of TNF-related apoptosis-inducing ligand (TRAIL) death receptor functions: emerging role of nuclear TRAIL-R2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

A novel juxtamembrane domain in tumor necrosis factor receptor superfamily molecules activates Rac1 and controls neurite growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The plasticity of regulatory T cell function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Metastasis suppressor function of tumor necrosis factor-related apoptosis-inducing ligand-R in mice: implications for TRAIL-based therapy in humans?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory "FADDosome" Complex upon TRAIL Stimulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Getting TRAIL back on track for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Superior serum half life of albumin tagged TNF ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Onto better TRAILs for cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung c

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Multivalent scaffold proteins as superagonists of TRAIL receptor 2-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Is TRAIL the holy grail of cancer therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Systematic identification of genomic markers of drug sensitivity in cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Potential Role of TRAIL in Metastasis of Mutant KRAS Expressing Lung Adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Combination immunotherapy: a road map.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4(+)CD25 (+) Treg apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Identification of RIP1 kinase as a specific cellular target of necrostatins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

RIP kinases at the crossroads of cell death and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

RIP3 mediates the embryonic lethality of caspase-8-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Survival function of the FADD-CASPASE-8-cFLIP(L) complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Functional complementation between FADD and RIP1 in embryos and lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL induces receptor-interacting protein 1-dependent and caspase-dependent necrosis-like cell death under acidic extracellular conditions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAF2 is a biologically important necroptosis suppressor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

The TRAIL apoptotic pathway in cancer onset, progression and therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Molecular and genetic properties of tumors associated with local immune cytolytic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

X-linked IAP is a direct inhibitor of cell-death proteases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

XIAP discriminates between type I and type II FAS-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.28

Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage

31 March 2020

1 reference

12 December 2020

tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c

1 reference

12 December 2020

Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen

1 reference

12 December 2020

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer

1 reference

12 December 2020

Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens

1 reference

12 December 2020

Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety

1 reference

12 December 2020

The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research

1 reference

12 December 2020

Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2017.28

1 reference

11 September 2017

1 reference